2 Pekeris Street
Tel: 609-718-2305 or 972-3-912-5853
Fax: +972 8 936 8584
About NeoTXNeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.
CEO: Asher Nathan PhD
CMO: Marcel Rozencweig MD
COO: Ramona Lloy PhD R.A.C.
CFO: Robert Harow
CSO: Roger Kornberg PhD
VP, R&D: Michal Shahar PhD
Please click here for NeoTX's pipeline.
7 articles with NeoTX
NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate
Phase 2a trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021
NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted cancer immunotherapies, today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. Chief Executive Officer, Asher Nathan, will deliver a corporate update to potential investors and strategic partners, among other various re
NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection platform to develop targeted anticancer immunotherapies, has closed a $45 million Series C financing.
NeoTX Therapeutics, Ltd. announced a presentation on the company’s lead candidate from its Selective T cell Redirection platform, naptumomab estafenatox, at the Society for Immunotherapy of Cancer’s 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.
11/4/2019Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
NeoTX Therapeutics, Ltd. announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox in combination with AstraZeneca’s checkpoint inhibitor IMFINZI® for the treatment of advanced or metastatic solid tumors.